EDX EDX Medical Group Plc

TIDMEDX

RNS Number : 8843N

EDX Medical Group PLC

27 September 2023

EDX Medical Group PLC

Annual General Meeting

Result of Annual General Meeting

The Annual General Meeting of EDX Medical Group Plc was held at Roosevelt Room, Brown's Hotel, 33 Albemarle St, London, W1S 4BP on 27 September 2023 at 2:00 p.m.

All seven resolutions put to members were passed on a poll. Resolutions 1 to 5 were passed as ordinary resolutions and resolutions 6 and 7 were passed as special resolutions.

The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:

 
  Resolution                           Votes for     %        Votes against   %      Votes withheld 
 Resolution 1 (Ordinary) 
  To elect Jason Holt as 
  a director of the Company            148,033,333   100.00   0               0.00   0 
                                      ------------  -------  --------------  -----  --------------- 
 Resolution 2 (Ordinary) 
  To elect Dr Michael Hudson 
  as a director of the Company         148,033,333   100.00   0               0.00   0 
                                      ------------  -------  --------------  -----  --------------- 
 Resolution 3 (Ordinary) 
  To elect Professor Sir 
  Christopher Evans OBE as 
  a director of the 
  Company                              148,033,333   100.00   0               0.00   0 
                                      ------------  -------  --------------  -----  --------------- 
 Resolution 4 (Ordinary) 
  To elect Professor Trevor 
  Jones CBE as a director 
  of the Company                       148,033,333   100.00   0               0.00   0 
                                      ------------  -------  --------------  -----  --------------- 
 Resolution 5 (Ordinary) 
  To authorise the Directors 
  to allot shares in the 
  Company                              148,033,333   100.00   0               0.00   0 
                                      ------------  -------  --------------  -----  --------------- 
 Resolution 6 (Special) 
  To disapply statutory pre-emption 
  rights generally                     148,033,333   100.00   0               0.00   0 
                                      ------------  -------  --------------  -----  --------------- 
 Resolution 7 (Special) 
  To disapply statutory pre-emption 
  rights pursuant to an acquisition 
  or other capital investment          148,033,333   100.00   0               0.00   0 
                                      ------------  -------  --------------  -----  --------------- 
 

As at 27 September 2023, there were 291,875,000 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.

Contacts:

 
 EDX Medical PLC 
 Dr Mike Hudson (Chief        +44 (0)7812 345 301 
  Executive Officer)           mike@edxmedical.co.uk 
 
 Oberon Capital 
 Nick Lovering (Corporate 
  Adviser) 
  Adam Pollock (Corporate 
  Broking) 
  Mike Seabrook (Corporate 
  Broking)                    +44 (0)20 3179 5300 
 
 Media House International 
 Ramsay Smith (Executive      +44 (0)7788 414856 
  Director)                    ramsay@mediahouse.co.uk 
                               +44 (0)7834 694609 
  Gary McQueen (Associate      gary@mediahouse.co.uk 
  Director) 
 

Notes for Editors:

About EDX Medical Group

www.edxmedical.co.uk

EDX Medical Group PLC develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical operates a molecular biology and diagnostics laboratory in Cambridge, UK, and the 100%-owned subsidiary "Torax Biosciences Ltd" ( www.toraxbiosciences.co.uk ) with a satellite operation in Ireland. EDX Medical provides testing and genomic sequencing services, undertakes quality assurance, conducts research & development (R&D) and has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485. Key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXEASNXAFDDEFA

(END) Dow Jones Newswires

September 27, 2023 11:16 ET (15:16 GMT)

EDX Medical (AQSE:EDX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

EDX Medical (AQSE:EDX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024